BOTHELL, Wash., March 13 /PRNewswire-FirstCall/ -- Helix BioMedix, Inc.
(OTC Bulletin Board: HXBM.OB), a developer of bioactive peptides, today
announced that the company has raised gross proceeds of approximately
$2.6 million from a recent equity private placement.
The company issued a total of 2,598,000 shares of its common stock and
warrants to purchase an additional 259,800 shares of its common stock to
accredited investors. The warrants have a 5-year term and a per share
exercise price of $1.00. The proceeds of the offering will be used to
continue ongoing research and development efforts, the out-licensing
initiatives for the company's peptides and for general corporate purposes.
About Helix BioMedix
Helix BioMedix, Inc. is a late stage biopharmaceutical company that has a
portfolio of issued patents that covers six distinct classes of peptides,
including over 100,000 unique peptide sequences. The company's mission is to
become the industry leader in developing and commercializing small proteins
known as bioactive peptides. The antimicrobial and wound healing properties of
these peptides qualify them for inclusion in a wide range of both
pharmaceutical and consumer products. The company is currently focused on the
development of selected peptides as topical anti-infectives and in wound
healing. Non-pharmaceutical applications being pursued by Helix BioMedix
include adjuvants for cosmetics/cosmeceuticals, personal care, plant health,
animal health and wide-spectrum biocides. More information about the company
and its proprietary peptides can be found on the company's website at
http://www.helixbiomedix.com.
Important Notice
This press release contains forward-looking statements (statements which
are not historical facts) within the meaning of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements involve risks
and uncertainties, including activities, events or developments that the
company expects, believes or anticipates will or may occur in the future. A
number of factors could cause actual results to differ from those indicated in
the forward-looking statements, including the company's ability to
successfully raise additional capital, enter into revenue generating license
agreements, continue its research and development efforts, including pre-
clinical and clinical studies, and general economic conditions. Additional
assumptions, risks and uncertainties are described in detail in our reports
and other filings with the Securities and Exchange Commission. Such filings
are available on our website or at http://www.sec.gov. Readers are cautioned that
such forward-looking statements are not guarantees of future performance and
that actual results or developments may differ materially from those set forth
in the forward-looking statements. The company undertakes no obligation to
publicly update or revise forward-looking statements to reflect subsequent
events or circumstances.
Contact: David H. Kirske of Helix BioMedix, Inc., +1-425-402-8400, or
dkirske@helixbiomedix.com, or investor relations, Alison Ziegler of Cameron
Associates, +1-212-554-5469, or alison@cameronassoc.com, for Helix BioMedix.
SOURCE Helix BioMedix, Inc.
 back to top
Related links:
http://www.helixbiomedix.com
CONTACT:
David H. Kirske of Helix BioMedix, Inc.,
+1-425-402-8400, or dkirske@helixbiomedix.com, or investor
relations, Alison Ziegler of Cameron Associates, +1-212-554-5469,
or alison@cameronassoc.com, for Helix BioMedix
|
